INDGN Stock Overview
Operates as a life sciences commercialization company in India, the United States, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for INDGN from our risk checks.
My Notes
Capture your thoughts, links and company narrative
Indegene Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹587.70 |
| 52 Week High | ₹736.30 |
| 52 Week Low | ₹470.10 |
| Beta | 0 |
| 1 Month Change | -8.30% |
| 3 Month Change | -11.26% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 30.02% |
Recent News & Updates
Recent updates
Shareholder Returns
| INDGN | IN Life Sciences | IN Market | |
|---|---|---|---|
| 7D | -0.3% | -1.3% | -4.2% |
| 1Y | n/a | 49.7% | 19.1% |
Return vs Industry: Insufficient data to determine how INDGN performed against the Indian Life Sciences industry.
Return vs Market: Insufficient data to determine how INDGN performed against the Indian Market.
Price Volatility
| INDGN volatility | |
|---|---|
| INDGN Average Weekly Movement | 6.2% |
| Life Sciences Industry Average Movement | 6.2% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in IN Market | 9.0% |
| 10% least volatile stocks in IN Market | 4.1% |
Stable Share Price: INDGN has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: INDGN's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 4,367 | Manish Gupta | www.indegene.com |
Indegene Limited operates as a life sciences commercialization company in India, the United States, Europe, and internationally. It operates through three segments: Enterprise Medical Solutions, Enterprise Commercial Solutions, and Omnichannel Activation & Others. The company develops biotech and medical device for biopharmaceutical, emerging biotech, and medical device companies.
Indegene Limited Fundamentals Summary
| INDGN fundamental statistics | |
|---|---|
| Market cap | ₹140.62b |
| Earnings (TTM) | ₹3.73b |
| Revenue (TTM) | ₹27.10b |
37.7x
P/E Ratio5.2x
P/S RatioIs INDGN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| INDGN income statement (TTM) | |
|---|---|
| Revenue | ₹27.10b |
| Cost of Revenue | ₹588.00m |
| Gross Profit | ₹26.51b |
| Other Expenses | ₹22.78b |
| Earnings | ₹3.73b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 15.59 |
| Gross Margin | 97.83% |
| Net Profit Margin | 13.77% |
| Debt/Equity Ratio | 0% |
How did INDGN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 21:47 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Indegene Limited is covered by 5 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Rajiv Berlia | Citigroup Inc |
| Rishi Jhunjhunwala | IIFL Research |
| Ankur Rudra | J.P. Morgan |